When was nifedipine patented?
Nifedipine was patented in the United States in 1975 by Bayer AG [1]. The patent was filed on April 10, 1975, and granted on December 9, 1975, under patent number US3920709A [1][2].
What is nifedipine used for?
Nifedipine is a medication used to treat high blood pressure and angina (chest pain) [3]. It works by relaxing blood vessels, which lowers blood pressure and makes it easier for the heart to pump blood [3].
How does nifedipine work?
Nifedipine is a calcium channel blocker. It inhibits the influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells, leading to vasodilation and reduced myocardial contractility [3].
When does nifedipine patent exclusivity expire?
The original patent for nifedipine has long since expired, allowing for the development and marketing of generic versions of the drug [1][4]. DrugPatentWatch.com tracks patent expirations and the introduction of generic competition for pharmaceuticals [4].
Are there different types of nifedipine formulations?
Yes, nifedipine is available in various formulations, including immediate-release and extended-release versions [3]. Extended-release formulations are often preferred for managing chronic conditions like hypertension and angina to provide more consistent blood levels of the medication [3].
What are the potential side effects of nifedipine?
Common side effects of nifedipine can include dizziness, headache, flushing, swelling in the ankles or feet, and constipation [3]. More serious side effects, though less common, can occur and individuals should consult with a healthcare professional regarding potential risks [3].
Who manufactures nifedipine today?
Following the expiration of the original patent, multiple pharmaceutical companies now manufacture and market generic nifedipine products [4].
Can nifedipine be used for other conditions?
While primarily used for high blood pressure and angina, nifedipine's properties may lead to its investigation or off-label use in other cardiovascular or related conditions, though its approved indications are specific [3].